News Release

AGA releases official guidance for patients with IBD during the COVID-19 pandemic

Many patients with IBD who develop COVID-19 should stop their medication

Peer-Reviewed Publication

American Gastroenterological Association

Decision Support Tool

image: Management of Patients with IBD during the COVID-19 Pandemic view more 

Credit: American Gastroenterology Association

Bethesda, Maryland (April 10, 2020) -- Today, the American Gastroenterological Association (AGA) published new COVID-19 guidance for gastroenterologists treating patients with inflammatory bowel disease (IBD): AGA Clinical Practice Update on Management of Inflammatory Bowel Disease During the COVID-19 Pandemic: Expert Commentary.

While the COVID-19 pandemic is a global health emergency, patients with IBD have particular concerns for their risk for infection and management of their medical therapies. This clinical practice update incorporates the emerging understanding of COVID-19 and summarizes available guidance for patients with IBD and the providers who take care of them.

Recommendations for gastroenterologists & their patients who have IBD:

    1. During this pandemic, patients with IBD should continue IBD therapies including scheduled infusions.

    2. Having IBD does not appear to increase the risk of SARS-CoV-2 infection or the development of COVID-19.

    3. Instructions for patients with IBD who develop COVID-19 (fever, respiratory symptoms, digestive symptoms, etc.):

      a. Stop thiopurines, methotrexate, tofacitinib.

      b. Stop biological therapies (including anti-TNF, ustekinumab, vedolizumab).

      c. Can restart therapies after complete resolution of COVID-19 symptoms. Patients should

      always speak with their health care team before stopping any medication.

    4. Doctors should submit cases of IBD and confirmed COVID-19 to the SECURE-IBD registry at


This paper, authored by leading IBD experts David T. Rubin, Joseph D. Feuerstein, Andrew Y. Wang, and Russell D. Cohen, is published in Gastroenterology, the official journal of the AGA. This expert commentary was commissioned and approved by the AGA Institute Clinical Practice Updates Committee and the AGA Governing Board to provide timely perspective on a topic of high clinical importance to AGA membership.


Download decision support tool & quick reference chart for social sharing.


Inflammatory bowel disease (IBD) is a group of chronic immune disorders, including Crohn's disease and ulcerative colitis. These conditions can cause abdominal pain, diarrhea and weight loss. Symptoms and progression of the disease can often be controlled by medication, but sometimes surgery is needed, as well. In the U.S., 3.1 million people have IBD. Learn more about IBD in the AGA GI Patient Center.


Rubin DT, Feuerstein JD, Wang AY, Cohen RD, AGA Clinical Practice Update on Management of Inflammatory Bowel Disease During the COVID-19 Pandemic: Expert Commentary, Gastroenterology (2020),

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.